CD8A and neoplasm: The simultaneous release of oxalilplatin and indoximod triggers a potent ICD of the pancreatic tumoral cells, followed by a reduction in the immunosuppressive tumoral microenvironment, which leads to recruitment of cytotoxic CD8+ T lymphocytes, depletion of Tregs, and significant tumor shrinkage.